AI in drug discovery hopes mount

PARAGRAPH 1 --- What happened: Takeda Pharmaceutical has partnered with Insilico Medicine to use AI for drug discovery, joining Eli Lilly, Novo Nordisk, Alnylam, AstraZeneca, J&J, and Novo Nordisk in leveraging AI to accelerate and improve drug development. Absci, a generative AI protein drug designer, has secured partnerships with Merck and Owkin. Anthropic, a tech company, has launched an AI drug discovery program. AI is expected to halve drug development time and boost success rates.

PARAGRAPH 2 --- Market impact: The pharmaceutical sector is experiencing a significant shift, with AI transforming drug discovery and development. Companies like Eli Lilly, Novo Nordisk, and AstraZeneca are seeing accelerated drug pipelines and improved financial performance. AI-focused biotechs like Absci and Insilico Medicine are attracting partnerships and investment. Tech giants like Anthropic are entering the healthcare market, driving competition and innovation.

PARAGRAPH 3 --- What to watch next: In Q3 2023, investors should watch for updates on AI-driven drug candidates from Eli Lilly, Novo Nordisk, and AstraZeneca. Absci's clinical progress and royalty agreements will be crucial for its long-term upside. In Q4 2023, J&J's AI-driven drug leads are expected to emerge, potentially accelerating its pipeline. Anthropic's AI drug discovery program progress will be a key indicator of tech giants' success in healthcare.